Highest-materiality recent filing
AXIL Brands Q4 revenue $8.6M (+48.9%), net income $1.5M; FY net income $2.7M
Q4 net revenues $8.6M, up 48.9% YoY; gross margin 72.0% vs 70.0%.
AXIL Brands Q3 net income falls to $0.2M; revenue +5.4% to $7.3M; guides Q4 rev $8-$10M
Net income $0.2M ($0.02 diluted EPS) vs $0.6M ($0.07) prior year; adjusted EBITDA $0.5M vs $0.9M.
AXIL Brands Q2 FY2026 net sales $8.1M (+5.2% YoY); net income $704,833; Walmart distribution deal
Net sales of $8.1M, up 5.2% from $7.7M; net income rose to $704,833 from $633,706 YoY.
AXIL Brands Q1 FY2026 revenue $6.9M (+17%), net income $0.3M vs loss of $0.1M YoY
Net sales $6.9M (+17.2% YoY); diluted EPS $0.04 vs $(0.02) loss; operating income $0.4M vs loss of $0.1M.
AXIL Brands reports FY2025 net income of $0.9M; secures major wholesale partnership
Net sales $26.3M vs $27.5M prior year; net income declined to $0.9M from $2.0M.
AXIL Brands Q3 FY2025 revenue up 6% to $6.9M; Adj EBITDA swings to positive $0.9M
Revenue $6.9M vs $6.5M YoY; gross margin 71.7% (vs 71.5%).
AXIL Brands Q2 FY2025 revenue down 8% to $7.7M; net income falls to $0.6M
Revenue $7.7M vs $8.4M prior year (-8%); gross margin 71.1% vs 74.3%.
AXIL Brands provides update: EPS up 380% YoY, shares reduced 55% via buyback
Stock buyback reduced fully diluted shares by ~55%; EPS increased 380% YoY last quarter, or 900% on post-buyback basis.
Q3 net sales $6.47M (+14.4% YoY); net income $781K vs $162K prior year; diluted EPS $0.04.
AXIL repurchases ~207.7M Series A Preferred shares for $1.25M cash; 42.3M remain
Repurchased 207,748,250 Series A Preferred (equiv. ~10,387,413 common shares) for $1,246,489.50 cash.
Reviv3 to uplist to NYSE American on Feb 14, rename to AXIL Brands, ticker 'AXIL'
Common stock approved for listing on NYSE American; trading begins Feb 14, 2024 under symbol AXIL.
Reviv3 Procare Q2 FY2024 net sales up 25.1% to record $8.4M, net income up 40.1% to $1.02M
Net sales record $8.4M (Q2 Nov 30, 2023) vs $6.7M a year ago, up 25.1%.
Reviv3 Procare Q1 net sales up 44.1% to $6.1M, net income down 12%
Net sales for quarter ended Aug 31, 2023: $6.1M vs $4.2M prior year (+44.1%).
Reviv3 Procare reports FY2023 revenue up 907% to $23.52M; net income of $1.82M vs loss
Net sales $23.52M for FY ended May 31, 2023, up 907% from $2.34M prior year.
Reviv3 Procare reports record Q2 FY2023 revenue of $6.7M, up 1,264% YoY
Q2 FY2023 revenue $6,731,999 vs $493,816 prior year, a 1,264% increase driven by hearing product acquisition.
Reviv3 Procare appoints Meenu Jain as CFO, replacing Christopher Go; $140k salary, 300k stock option
Meenu Jain appointed CFO effective Nov 1, 2022; Christopher Go remains Secretary.
Reviv3 Procare Q1 FY2023 revenue $4.24M, up 405% YoY; net income before tax $0.25M
Revenue $4.24M, up 405% YoY from $0.84M; gross profit margin improved to 77% from 57%.
Reviv3 reports FY2022 revenue up 43% to $2.3M; expects Q1 FY2023 revenue over $3.4M
Revenue $2,336,257, up 43% from $1,633,609 in prior year.
Axil's 2021 net sales $13.6M, net loss $2.4M; 2020 net income $952k.
Purchase price: 73.2M common shares and 250M non-voting Series A Preferred shares, aggregate value $32.3M.
Purchase price of $33.3M via 73.2M common shares and 250M non-voting preferred shares convertible 1:1; 25.9% discount to 22-day VWAP.
As previously announced, effective April 30, 2024, Monica Diaz Brickell left AXIL Brands, Inc. (the “Company”), including her position as the Chief Financial Officer of the Company.
Effective April 30, 2024, Monica Diaz Brickell left the Company, including her position as the Chief Financial Officer of the Company.
appointed Jeff Brown, Chief Operating Officer of the Company, as Chief Financial Officer and Chief Operating Officer of the Company, effective as of May 1, 2024.
appointed Jeffrey Brown, Peter Dunne, and Manu Ohri to the Board
appointed Jeffrey Brown, Peter Dunne, and Manu Ohri to the Board
appointed Jeffrey Brown, Peter Dunne, and Manu Ohri to the Board
On April 24, 2023, the Company appointed Monica Diaz Brickell, aged 44, to serve as the Company’s Chief Financial Officer.
On April 21, 2023, Meenu Jain notified Reviv3 Procare Company (the “Company”) that she will be stepping down as Chief Financial Officer of the Company effective at 4:00 p.m. (Pacific Time) on April 21, 2023, for personal reasons.
Effective November 1, 2022, Reviv3 Procare Company (the “Company”) its Board of Directors (the “Board”) appointed Meenu Jain as Chief Financial Officer of the Company, succeeding Christopher Go in such position.
Effective as of November 1, 2022, Christopher Go will continue to serve as Secretary of the Company.
Max materiality 0.85 · Median 0.60 · Most common event earnings